Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways

Molecular Medicine Reports

Volumn 4, Issue 5, 2011, Pages 985-992

  Liu, Hai Zhong ^a   Yu, Chao ^a   Yang, Zhu ^a   He, Jun Lin ^a   Chen, Wen Juan ^a   Yin, Juan ^a   Li, Wen Ming ^a   Liu, Hong Tao ^a   Wang, Ying Xiong ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; Ovarian cancer; Signaling pathway; Tubeimoside I

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CISPLATIN; GLUTATHIONE TRANSFERASE P1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2; TRITERPENOID; TUBEIMOSIDE I; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CYTOTOXICITY; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION;

BCL-2-ASSOCIATED X PROTEIN; CALCIUM; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MAP KINASE SIGNALING SYSTEM; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; SAPONINS; TRITERPENES; UP-REGULATION;

EID: 79960398078     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.513     Document Type: Article

References (41)

1. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anticancer chemotherapy. Cancer Treat Rev 24: 331-344, 1998.
2. Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, Hood L and Lin B: Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 5: 433-443, 2006.
3. Vasey PA: Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 89: S23-S28, 2003.
4. Arafa el-SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA and Wani AA: Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res 69: 8910-8917, 2009.
5. Wang F, Ma R and Yu L: Role of mitochondria and mitochondrial cytochrome c in tubeimoside I-mediated apoptosis of human cervical carcinoma HeLa cell line. Cancer Chemother Pharmacol 57: 389-399, 2006.
6. Cory S and Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647-656, 2002. (Pubitemid 37328916)
7. Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T and Green DR: Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci USA 105: 20327-20332, 2008.
8. Tsujimoto Y and Shimizu S: VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ 7: 1174-1181, 2000. (Pubitemid 32042224)
9. Bishopric NH, Andreka P, Slepak T and Webster KA: Molecular mechanisms of apoptosis in the cardiac myocyte. Curr Opin Pharmacol 1: 141-150, 2001. (Pubitemid 33586404)
10. Maxwell SA, Acosta SA and Davis GE: Induction and alternative splicing of the Bax gene mediated by p53 in a transformed endothelial cell line. Apoptosis 4: 109-114, 1999. (Pubitemid 29378794)
11. Martinez-Caballero S, Dejean LM, Jonas EA and Kinnally KW: The role of the mitochondrial apoptosis induced channel MAC in cytochrome c release. J Bioenerg Biomembr 37: 155-164, 2005. (Pubitemid 41420470)
12. Galan-Moya EM, Hernandez-Losa J, Aceves Luquero CI, De la Cruz-Morcillo MA, Ramírez-Castillejo C, Callejas-Valera JL, Arriaga A, Aranburo AF, Ramón y Cajal S, Silvio Gutkind J, et al: c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy. Int J Cancer 122: 289-297, 2008. (Pubitemid 350234714)
13. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
14. Wada T and Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23, 2838-2849, 2004.
15. Bulavin DV and Fornace AJ Jr: p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 92: 95-118, 2004. (Pubitemid 39458114)
16. Mo Z, Gao Y, Cao Y, Gao F and Jian L: An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: a HuGE review. Prostate 69: 662-688, 2009.
17. Hayes JD and Strange RC: Glutathione S-transferase polymorphisms and their biological consequence. Pharmacology 61: 154-166, 2000.
18. Souiden Y, Mahdouani M, Chaieb K, Elkamel R and Mahdouani K: Polymorphisms of glutathione-S-transferase M1 and T1 and prostate cancer risk in a Tunisian population. Cancer Epidemiol 34: 598-603, 2010.
19. Rebbeck TR: Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 6: 733-743, 1997.
20. Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B and Yu H: Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 100: 330-337, 2006. (Pubitemid 43075265)
21. Prislei S, Mariani M, Raspaglio G, Mozzetti S, Filippetti F, Ferrandina G, Scambia G and Ferlini C: RON and cisplatin resistance in ovarian cancer cell lines. Oncol Res 19: 13-22, 2010.
22. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ and Li LZ: Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 295: 110-123, 2010.
23. Ohmichi M, Hayakawa J, Tasaka K, Kurachi H and Murata Y: Mechanisms of platinum drug resistance. Trends Pharmacol Sci 26: 113-116, 2005. (Pubitemid 40313588)
24. Sarkar FH and Li Y: Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66: 3347-3350, 2006.
25. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D and Anto RJ: Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280: 6301-6308, 2005. (Pubitemid 40341176)
26. Yu TX, Ma RD and Yu LJ: Structure-activity relationship of tubeimosides in anti-inflammatory, antitumor, and antitumor-promoting effects. Acta Pharmacol Sin 22: 463-468, 2001.
27. Cheng G, Zhang Y, Zhang X, Tang HF, Cao WD, Gao DK and Wang XL: Tubeimoside V (1), a new cyclic bisdesmoside from tubers of Bolbostemma paniculatum, functions by inducing apoptosis in human glioblastoma U87MG cells. Bioorg Med Chem Lett 16: 4575-4580, 2006. (Pubitemid 44094074)
28. Yu L, Ma R and Yu T: Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL-60) by Tubeimoside 1. Planta Med 62: 119-121, 1996. (Pubitemid 26163212)
29. Xu Y, Chiu JF, He QY and Chen F: Tubeimoside-1 exerts cytotoxicity in HeLa cells through mitochondrial dysfunction and endoplasmic reticulum stress pathways. J Proteome Res 8: 1585-1593, 2009.
30. Weng XY, Ma RD and Yu LJ: Apoptosis of human nasopharyngeal carcinoma CNE-2Z cells induced by tubeimoside I. Ai Zheng (in Chinese) 22: 806-811, 2003.
31. Ma R, Song G, You W, Yu L, Su W, Liao M, Zhang Y, Huang L, Zhang X and Yu T: Anti-microtubule activity of tubeimoside I and its colchicine binding site of tubulin. Cancer Chemother Pharmacol 62: 559-568, 2008.
32. Chen MJ, Nguyen TV, Pike CJ and Russo-Neustadt AA: Norepinephrine induces BDNF and activates the PI-3K and MAPK cascades in embryonic hippocampal neurons. Cell Signal 19: 114-128, 2007. (Pubitemid 44880248)
33. Chang CW, Tsai WH, Chuang WJ, Lin YS, Wu JJ, Liu CC, Tsai PJ and Lin MT: Procaspase 8 and Bax are up-regulated by distinct pathways in Streptococcal pyrogenic exotoxin B-induced apoptosis. J Biol Chem 284: 33195-33205, 2009.
34. Singhal PC, Bhaskaran M, Patel J, Patel K, Kasinath BS, Duraisamy S, Franki N, Reddy K and Kapasi AA: Role of p38 mitogen-activated protein kinase phosphorylation and Fas-Fas ligand interaction in morphine-induced macrophage apoptosis. J Immunol 168: 4025-4033, 2002. (Pubitemid 34298408)
35. Porras A, Zuluaga S, Black E, Valladares A, Alvarez AM, Ambrosino C, Benito M and Nebreda AR: P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol Biol Cell, 15: 922-933, 2004. (Pubitemid 38146504)
36. Strange RC, Spiteri MA, Ramachandran S and Fryer AA: Glutathione-S- transferase family of enzymes. Mutat Res 482: 21-26, 2001. (Pubitemid 32787078)
37. Terrier P, Townsend AJ, Coindre JM, Triche TJ and Cowan KH: An immunohistochemical study of pi class glutathione S-transferase expression in normal human tissue. Am J Pathol 137: 845-853,1990. (Pubitemid 20337799)
38. Orlandi A, Costantini S, Campione E, Ferlosio A, Amantea A, Bianchi L, Chimenti S and Spagnoli LG: Relation between animal-type melanoma and reduced nuclear expression of glutathione S-transferase pi. Arch Dermatol 145: 55-62, 2009.
39. Tsuchida S and Sato K: Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 27: 337-384, 1992.
40. Goto S, Kamada K, Soh Y, Ihara Y and Kondo T: Significance of nuclear glutathione S-transferase pi in resistance to anticancer drugs. Jpn J Cancer Res 93: 1047-1056, 2002. (Pubitemid 35154272)
41. Cheng X, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Okada M and Terakawa N: Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer 179: 521-527, 1997. (Pubitemid 27051777)